Successful treatment of unresectable advanced melanoma by administration of nivolumab with ipilimumab before primary tumor resection

Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Ryo Tanita Amagai, Akira Hashimoto, Takanori Hidaka, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma-reactive T cells at the primary site of melanoma and has a high rate of histological complete response, the pre-surgical administration of this combination could be the optimal therapy for unresectable advanced melanoma. In this report, a case of unresectable advanced melanoma treated successfully with administration of nivolumab with ipilimumab before primary tumor resection is presented. In addition, CD8+ T cells increased among the tumor-infiltrating lymphocytes that were surrounding melanoma cells and caspase 3+ cells. The present case suggests that pre-surgical administration of nivolumab with ipilimumab could be the optimal therapy for the treatment of unresectable advanced melanoma.

Original languageEnglish
Article number140
JournalFrontiers in Medicine
Volume6
DOIs
Publication statusPublished - 2019

Keywords

  • Advanced melanoma
  • Ipilimumab
  • Nivolumab
  • Pre-surgical administration
  • T cell expansion

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Successful treatment of unresectable advanced melanoma by administration of nivolumab with ipilimumab before primary tumor resection'. Together they form a unique fingerprint.

Cite this